[HTML][HTML] A human monoclonal antibody blocking SARS-CoV-2 infection
Nature communications, 2020•nature.com
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused
a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted
therapeutics for treatment of this disease are currently lacking. Here we report a human
monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This
cross-neutralizing antibody targets a communal epitope on these viruses and may offer
potential for prevention and treatment of COVID-19.
a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted
therapeutics for treatment of this disease are currently lacking. Here we report a human
monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This
cross-neutralizing antibody targets a communal epitope on these viruses and may offer
potential for prevention and treatment of COVID-19.
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
nature.com